[ad_1] HONG KONG, Dec. 10, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific […]
Tag: International Medical Approval
The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.
[ad_1] NANJING, China, Oct. 9, 2024 /PRNewswire/ — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”) announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, […]
